key: cord-1003783-q3uxoq7a
authors: Stattin, K.; Lipcsey, M.; Andersson, H.; Pontén, E.; Bülow Anderberg, S.; Gradin, A.; Larsson, A.; Lubenow, N.; von Seth, M.; Rubertsson, S.; Hultström, M.; Frithiof, R.
title: Inadequate prophylactic effect of low-molecular weight heparin in critically ill COVID-19 patients
date: 2020-09-03
journal: J Crit Care
DOI: 10.1016/j.jcrc.2020.08.026
sha: a53195fdd205f1d1f6ca969d8b7e24e67831d8fe
doc_id: 1003783
cord_uid: q3uxoq7a

PURPOSE: The aim of this study was to investigate potential markers of coagulopathy and the effects of thromboprophylaxis with low-molecular-weight heparin (LMWH) on thromboelastography (TEG) and anti-factor Xa in critically ill COVID-19 patients. MATERIAL AND METHODS: We conducted a prospective study in 31 consecutive adult intensive care unit (ICU) patients. TEG with and without heparinase and anti-factor Xa analysis were performed. Standard thromboprophylaxis was given with dalteparin (75–100 IU/kg subcutaneously). RESULTS: Five patients (16%) had symptomatic thromboembolic events. All patients had a maximum amplitude (MA) > 65 mm and 13 (42%) had MA > 72 mm at some point during ICU stay. Anti-factor Xa activity were below the target range in 23% of the patients and above target range in 46% of patients. There was no significant correlation between dalteparin dose and anti-factor Xa activity. CONCLUSIONS: Patients with COVID-19 have hypercoagulability with high MA on TEG. The effect of LMWH on thromboembolic disease, anti-factor Xa activity and TEG was variable and could not be reliably predicted. This indicates that standard prophylactic doses of LMWH may be insufficient. Monitoring coagulation and the LMWH effect is important in patients with COVID-19 but interpreting the results in relation to risk of thromboembolic disease poses difficulties.

Patients with Corona virus disease 2019 (COVID-19) have been reported prone to develop thrombotic and thromboembolic disease. [1] [2] [3] [4] Microthrombosis has been suggested to contribute to both respiratory failure and neurological complications [5, 6] and emerging data describe coagulation abnormalities as a marker of poor prognosis. [7] [8] [9] Low molecular weight heparins (LMWH) are often prescribed to decrease the risk of thromboembolic complications in hospitalized patients and treatment with LMWH was recently shown to reduce mortality in high-risk patients with COVID-19. [10] However, data is limited on the mechanisms underlying the coagulation deficits associated with COVID-19 and how they are affected by LMWH.

J o u r n a l P r e -p r o o f Thromboelastography (TEG) offers a comprehensive assessment of coagulation in whole blood samples, describing plasmatic coagulation as well as platelet function and fibrinolysis.

Furthermore, the addition of heparinase to the sample eliminates the iatrogenic heparin effect in blood samples thus allowing estimation of the effect of LMWH.

The aim was to characterize coagulation abnormalities and the effect of LMWH with respect to TEG profile with and without heparinase, anti-factor Xa activity and clinical manifestations (i.e. bleeding and thrombosis) in 31 COVID-19 patients admitted to intensive care units at Uppsala University Hospital, Uppsala, Sweden.

The study was approved by the National Ethical Review Agency (EPM; No. 2020-01623).

Informed consent was obtained from the patient, or next of kin if the patient was unable give consent. The Declaration of Helsinki and its subsequent revisions were followed. The protocol of the study was registered a priori (ClinicalTrials ID: NCT04316884). STROBE guidelines were followed for reporting. This prospective observational study was performed at a mixed surgical/medical intensive care unit (ICU) at Uppsala University Hospital, a tertiary care hospital in Sweden.

All adult patients with COVID-19 consecutively admitted to the ICU March 13 th to April 14 th 2020 with informed consent and routinely performed TEG results accessible were included in the study. COVID-19 was diagnosed with positive reverse-transcription polymerase chain reaction (RT-PCR) on nasopharyngeal swabs.

Dalteparin (Fragmin®, Pfizer AB, Sollentuna, Sweden) subcutaneously was used for thrombosis prophylaxis. COVID-19 patients with body weight below 70 kg were given 5000 J o u r n a l P r e -p r o o f Journal Pre-proof IU dalteparin, those with body weight 70-90 kg were given 7500 IU dalteparin and those above 90 kg were given 10 000 IU dalteparin. The anti-factor Xa target range for thrombosis prophylaxis was 0.2-0.4 kIU/L. [11] Clinical data were recorded prospectively daily. Simplified acute physiology score 3 (SAPS3), [12] renal function, circulatory support and respiratory support data were collected as reported in the results. Blood samples were collected on ICU admission and daily during the ICU stay. Blood count (CBC), high sensitivity C-reactive protein (CRP), kidney and liver function tests were performed. CBC was analyzed on a Sysmex XN™ instrument (Sysmex, Kobe, Japan) while hsCRP, ferritin, kidney and liver markers were analyzed on an Architect ci16200 (Abbott Laboratories, Abbott Park, IL, US).

The viscoelastic properties were analyzed using the TEG 6s® platform (Haemonetics, Boston, MA), [13] the citrated multichannel cartridge facilitates the simultaneous performance of the 

A total of 31 patients diagnosed with COVID-19 treated in ICU were enrolled in the study.

Characteristics of patients with and without thromboembolic events in the study cohort are listed in Table 1 . Most patients were male and the median BMI in the cohort was 30. One fourth of the cohort had a history of smoking, but ongoing smoking was unusual. The most common comorbidities were hypertension, diabetes mellitus and chronic lung disease.

The median ICU admission was 10 days after the initial COVID-19 symptoms. During their ICU stay 24 patients (77%) were subjected to invasive ventilation and 25 patients (81%) were treated with vasopressors (noradrenalin) at some point. No major changes were seen in laboratory variables during the ICU stay, except for decreasing CRP (Table 3 ).

In the patients without thromboembolic events, i.e. with prophylaxis dose of dalteparin, 6 of the 26 (23%) had an anti-factor Xa at least once below the target range, while 12 of 26 (46%) had and anti-factor Xa at least once above the target range. There was no correlation between dalteparin dose and anti-factor Xa ( Figure 1 ).

In this cohort study of 31 COVID-19 patients admitted to intensive care, a majority of patients show a hyper-coagulopathic phenotype during the course of illness. Further, standard prophylactic doses of LMWH may be insufficient to protect patients from thromboembolic complications. Analysis of anti-factor Xa activity and TEG appear inadequate to monitor the effect of LMWH in these patients. The present study reports the results of 31 patients using TEG, showing that hypercoagulability is a general feature across this population. This was seen in the form of increased maximum amplitude (MA) but not as a decreased R-time. This is in partial agreement with previous studies that have shown both decreased clot formation time and increased maximum amplitude. [15, 16] A greater than normal MA has been able to predict thromboembolism in trauma and postoperatively. [17] [11] despite normal dosing. This may lead to the conclusion that measuring anti-factor X activation may be useful. However, our results indicate that COVID-19 may be associated with thromboembolic complications even with anti-factor Xa activation J o u r n a l P r e -p r o o f Journal Pre-proof in the accepted prophylactic range. This prompts for vigilance as it suggests that it may be difficult to predict the risk of thromboembolic complications using standard tests, and equally hard to safely conclude that a patient has adequate treatment with LMWH.

Strengths of this study includes data from TEG with and without heparinase, allowing assessment of heparin effects. Weaknesses include the relatively low number of patients and events and the fact that a number of patients in the study still receive critical care. 

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Facing COVID-19 in ICU: vascular dysfunction, thrombosis, and dysregulated inflammation

Pulmonary Embolism Hospitalizations and Use of Inferior Vena Caval Filters in Older Adults: National Study of Medicare Beneficiaries

COVID-19 Complicated by Acute Pulmonary Embolism

Nervous system involvement after infection with COVID-19 and other coronaviruses

Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan: A Retrospective Observational Study

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical Characteristics of Coronavirus Disease 2019 in China

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

The Anti-Factor Xa Range For Low Molecular Weight Heparin Thromboprophylaxis

SAPS 3--From evaluation of the patient to evaluation of the intensive care unit. Part 2: Development of a prognostic model for hospital mortality at ICU admission

New-Generation Thromboelastography: Comprehensive Evaluation of Citrated and Heparinized Blood Sample Storage Effect on Clot-Forming Variables

The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome

COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure

Hypercoagulability of COVID-19 patients in Intensive Care Unit. A Report of Thromboelastography Findings and other Parameters of Hemostasis

The Ability of Thromboelastography to Detect Hypercoagulability

KCH: kaolin with heparinase, Lys30: Clot lysis at 30 minutes, MA: maximum amplitude, R: reaction time

We thank Research nurses Joanna Wessbergh and Elin Söderman for their expertise in compiling the study.

Sources of funding: The study was funded by Scilifelab, the Knut and Alice Wallenberg